Fig 1: Elevated serum NETs are associated with intestinal injury in abdominal sepsis patients.A Circulating cf-DNA and Cit H3-DNA complexes in abdominal sepsis patients (n = 5) and healthy controls (n = 5) were analyzed by ELISA. B Serum I-FABP and D-lactate were analyzed by ELISA. C Correlation between circulating NETs biomarkers (cf-DNA and Cit H3-DNA complex) and circulating intestinal injury biomarkers (I-FABP and D-lactate). NETs neutrophil extracellular traps, cf-DNA cell-free DNA, Cit H3 citrullinated histone 3, ELISA enzyme-linked immunosorbent assay, I-FABP intestinal fatty-acid binding protein. Data are expressed as the means ± SD. *P < 0.05; **P < 0.01.
Fig 2: Elevated NET levels are associated with intestinal necroptosis and gut barrier dysfunction in II/R patients. (A) Circulating MPO‐DNA and CitH3‐DNA complexes in healthy controls and II/R patients were analysed by ELISA. (B) Serum D‐lactate and I‐FABP were analysed by ELISA. (C) Correlation between circulating NETs biomarker (CitH3‐DNA) and circulating intestinal injury biomarkers (D‐lactate and I‐FABP). (D) Intestinal inflammatory factors (IL‐1β, IL‐6, TNF‐α and MCP‐1) detected by ELISA. (E,F) Comparisons of the histopathological changes using H&E and Masson staining and the Chiu scoring system. Scale bars = 500 μm. (G) Neutrophil infiltration (Ly6G) and NET formation (CitH3) were assessed by immunofluorescent staining. Scale bars = 100 μm. (H,I) The expression levels of TUNEL and p‐MLKL (a necroptotic biomarker) were analysed through immunofluorescence staining, and the numbers of TUNEL+ and p‐MLKL+ cells were counted. Scale bars = 100 μm. (J,K) NET formation (CitH3), necroptosis (p‐MLKL, MLKL) and intestinal tight junction proteins (claudin‐1 and occludin) were analysed by western blotting. Grayscale values were measured and quantified using ImageJ software. CitH3, citrullinated histone H3; H&E, haematoxylin–eosin; H3, histone H3; I‐FABP, intestinal fatty‐acid binding protein; II/R, intestinal ischemia–reperfusion; IL‐1β, interleukin 1β; IL‐6, interleukin 6; MCP‐1, monocyte chemoattractant protein 1; MPO, myeloperoxidase; NET, neutrophil extracellular trap; TNF‐α, tumour necrosis factor alpha. Data are shown as the means ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
Fig 3: SFI administration alleviated sepsis-induced intestinal injury. (A,B) The plasma levels of D-lactate and I-FABP in septic patients were measured (n = 10). (C) The plasma levels of DAO in septic mice treated with or without LSF and HSF were measured (n = 6). (D) H&E staining of the intestinal tissues. (E) Pathological evaluation of the intestinal injury using Chiu’s score (n = 6 per group). (F) The length of the villus in selected fields were measured (n = 6 per group). (G) The levels of lactate in the plasma were measured by lactate assay kit. *, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001.
Fig 4: Preoperative fecal GUS activity and NAR predict postoperative AGI risk after CPB(A–C) Perioperative plasma DAO, D-lactate, and I-FABP levels in AGI (n = 21) and non-AGI (NAGI, n = 86) patients at T1 (preoperative), T2 (at the end of operation), T3 (6 h postoperatively), and T4 (24 h postoperatively).(D) Schematic overview for predictive modeling using preoperative fecal biomarkers.(E and F) ROC analyses of individual fecal biomarkers for AGI prediction.(G) ROC analysis evaluating the combined fecal biomarker model for AGI risk.(H) ROC curve in the independent internal validation cohort (n = 196; AGI, n = 44; NAGI, n = 152) for the NAR + GUS nomogram model.(I) Calibration plot validating the AGI prediction nomogram.(J) Decision curve analysis of the nomogram across threshold probabilities.(K) Nomogram tool for preoperative bedside AGI risk assessment.(L) Framework for distinguishing mild from severe AGI using preoperative biomarkers.(M and N) ROC validation for severe AGI prediction in both training and independent internal validation cohorts.(O) Calibration curve for validation of severe AGI severity prediction model.(P) Decision curve analysis for clinical decision-making at severe AGI thresholds.(Q) Nomogram for rapid bedside assessment of postoperative AGI severity. Quantitative measurements of plasma biomarkers (DAO, D-lactate, and I-FABP) were performed in triplicate. Quantitative data are presented as mean ± SEM where applicable. Statistical significance was defined as p < 0.05. AUCs with 95% CIs were estimated by nonparametric bootstrapping (B = 2,000) and compared by DeLong’s test. Logistic regression models were constructed using stepwise selection. Calibration was assessed by 1,000 bootstrap resamples and the Hosmer-Lemeshow test. Clinical utility was evaluated by decision-curve analysis. Abbreviations: DAO, diamine oxidase; D-LA, D-lactate; I-FABP, intestinal fatty acid binding protein; ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval; SEM, standard error of the mean.
Supplier Page from CUSABIO Technology LLC for Human intestinal fatty acid binding protein,iFABP ELISA Kit